Vol. 4 No. 4 (2016)

Published: 26-12-2016

Reviews

ROCK inhibitors in ocular disease

Eva Halasz, Ellen Townes-Anderson

ADMET and DMPK, Vol. 4 No. 4 (2016), 280-301

Published 26-12-2016;

DOI: https://doi.org/10.5599/admet.4.4.331
- PDF

Original Scientific Articles

Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP)

Rhiannon N. Hardwick, Marina Snellings, Brian C. Ferslew, Yang Lu, Kim L.R. Browuer

ADMET and DMPK, Vol. 4 No. 4 (2016), 302-313

Published 26-12-2016;

DOI: https://doi.org/10.5599/admet.4.4.322
- PDF
Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer

Srinivas Maddi, Ravi Akkireddy, Srinivas Lenkalapelly, Pratima Srivastava, Joshodeep Boruwa, Chandra Deb, Arnab Roy Chowdhury, Duraiswamy A. Jeyaraj, Ramana Reddy, Premkumar Reddy, Manoj Maniar, Sachin Bansal, Jang B. Gupta

ADMET and DMPK, Vol. 4 No. 4 (2016), 314-326

Published 26-12-2016;

DOI: https://doi.org/10.5599/admet.4.4.341
- PDF
Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer

Richard J. Honeywell, Amir Avan, Elisa Giovannetti, Godefridus J. Peters

ADMET and DMPK, Vol. 4 No. 4 (2016), 327-334

Published 26-12-2016;

DOI: https://doi.org/10.5599/admet.4.4.335
- PDF
Investigation of biopharmaceutical and physicochemical drug properties suitable for orally disintegrating tablets

Asami Ono, Takumi Tomono, Takuo Ogihara, Katsuhide Terada, Kiyohiko Sugano

ADMET and DMPK, Vol. 4 No. 4 (2016), 335-360

Published 26-12-2016;

DOI: https://doi.org/10.5599/admet.4.4.338
- PDF

Reviews

ROCK inhibitors in ocular disease

Original Scientific Articles

Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP)

Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer

Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer

Investigation of biopharmaceutical and physicochemical drug properties suitable for orally disintegrating tablets

JIF

elsevier

links

Information